COVID-19

FAQs related to the coronavirus and its impact on how you use and prescribe Dexcom. This page will be updated with new information as it becomes available.

FAQs related to the coronavirus and its impact on how you use and prescribe Dexcom. This page will be updated with new information as it becomes available.

What is the Dexcom Patient Assistance Program for US Patients During the COVID-19 Pandemic?

The Dexcom Patient Assistance Program (“Program”) will be available to current U.S. customers who have lost their health insurance coverage as a result of the impact of the COVID-19 pandemic.* The Program will launch in the next several weeks and will be available during the COVID-19 pandemic in the United States.

For those existing U.S. customers who qualify for participation in Dexcom’s Program, Dexcom will offer:

Up to two shipments of 90-days of Dexcom continuous glucose monitoring (“CGM”) system supplies, with each shipment consisting of one transmitter and three boxes of three sensors
Reduce patient cost to $45 per 90-day supply shipment

Visit Dexcom.com/covid19-assistance for more information. 

*Patients that are eligible for coverage of their Dexcom CGM systems under a federal or state government program (such as Medicare, Medicaid or VA benefits) are not eligible to participate in this Program. Certain terms and conditions will apply to be eligible for participation in the Program, such as the submission of a complete Program application and documentation showing loss of healthcare benefits.

Can healthcare providers get reimbursed for telehealth CGM data consultations?*

Yes. Remote consultations using Dexcom CLARITY may still be eligible for reimbursement under billing code 95251. For resources to set up Dexcom CLARITY Clinic, please click here.

*The reimbursement information provided is intended to assist you with billing for your services related to continuous glucose monitoring (CGM). It is intended for informational purposes only and is not a guarantee of coverage and payment. Providers are encouraged to contact their local payers with questions related to coverage, coding, and payment.

Will the State of California's stay-at-home mandate affect your ability to produce Dexcom products?

No. While the State of California recently issued a stay-at-home order requiring non-essential businesses to close until further notice, the order does not apply to companies performing “essential” services or functions like Dexcom.

How can I continue to get CGM education while practicing social distancing?

CPE/CME courses are available for credit at cgmeducation.net. All courses are free online and available on demand.

How are Dexcom field employees responding to the COVID-19 situation regarding social distancing and home sheltering?

At Dexcom, we consider patient safety our number one priority. With the recent news of the impact COVID-19 is having across the US, we are aligned with community actions that will prevent the spread of the virus and have made the decision to have our field-based employees work from home. We will only allow our employees to enter your facility once it is determined safe to do so. In the meantime, diabetes will continue, and we want to make sure that you have all of the information you need to treat this at-risk population successfully. Our field and all supporting partners will be available via email, telephone, and video meetings to help you meet the needs of your patients with diabetes.

Will patients be able to order Dexcom products and supplies? Will they be able to order extra supplies?

Dexcom is still accepting orders for products and supplies at this time and does not currently anticipate any interruptions to our ability to produce and supply product, as a result of the coronavirus. However, to ensure supply continuity for all customers, we won’t be processing additional orders for supplies outside of what is covered by a patient’s insurance at this time.

How can my patients under home quarantine access their Dexcom products?

Patients can continue to get their products from the pharmacy or DME providers. Several national pharmacies are offering home delivery services. Please ask your patients to contact their preferred pharmacy or DME provider for options.

Who do patients contact if they have questions about their Dexcom products and supplies?

Dexcom will continue to process re-orders, but we ask that patients only contact the Customer Sales Support and Technical Support teams at 844-607-8398 with urgent requests at this time.

Answers to many common patient questions are available at dexcom.com/answers, and patients can submit web self-service tickets at dexcom.com/contact. Our team will work to expeditiously respond to those inquiries.

The Dexcom CARE team is also still available at dexcom.com/dexcom-care or 877-339-2664 to help patients that are new to Dexcom and need help getting started with their product.

Will there be delays in how and when patients receive their Dexcom products and supplies?

Dexcom does not currently anticipate any interruptions to our production abilities or capacities. However, we do anticipate delays in the near term related to our customer service and technical support, which means that patients should expect longer wait times on the phone. We appreciate your patients’ understanding and patience during this time.

Will patients still be able to use Dexcom apps and software during this time?

Yes. Dexcom apps and software will continue to operate without interruption, and the company does not anticipate any outages or delays due to the coronavirus situation. Patients may check the live status of each of our apps and software at status.dexcom.com.

Please click here for patient support and resources.

Contact Dexcom

If you are a clinician and want to learn more about Dexcom’s Continuous Glucose Monitoring Systems, please fill out the form and a Dexcom representative will contact you.

If you are a Dexcom User or Patient, please contact Dexcom here.

The information you provide will be sent securely and subject to the Dexcom Terms of Use and Privacy Policy.